Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect
News and Views Disease Lists/Categories
About
About MalaCards Datasets Our Publications Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
MCID: HMP009
MIFTS: 41

Haemophilus Influenzae

Categories: Infectious diseases, Rare diseases
Genes Tissues Related diseases Publications Pathways Drugs
Sources

Aliases & Classifications for Haemophilus Influenzae

About this section

MalaCards integrated aliases for Haemophilus Influenzae:

Name: Haemophilus Influenzae 20
H. Influenzae 20

Classifications:

MalaCards categories:
Global: Rare diseases Infectious diseases
See all MalaCards categories (disease lists)
ICD10: 32


External Ids:

ICD10 32 B96.3
Sources

Summaries for Haemophilus Influenzae

About this section
MalaCards based summary : Haemophilus Influenzae, also known as h. influenzae, is related to epiglottitis and bacterial meningitis. An important gene associated with Haemophilus Influenzae is LACTB (Lactamase Beta), and among its related pathways/superpathways are IL-17 Family Signaling Pathways and Proteoglycans in cancer. The drugs Immunoglobulins and Antibodies have been mentioned in the context of this disorder. Affiliated tissues include neutrophil, bone marrow and eye, and related phenotype is homeostasis/metabolism.

Wikipedia : 74 Haemophilus influenzae (formerly called Pfeiffer's bacillus or Bacillus influenzae) is a Gram-negative,... more...

Sources

Related Diseases for Haemophilus Influenzae

About this section

Diseases related to Haemophilus Influenzae via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 570)
# Related Disease Score Top Affiliating Genes
1 epiglottitis 32.6 OMP LACTB
2 bacterial meningitis 31.7 TNF TLR2 LACTB CXCL8
3 meningitis 31.6 TNF TLR2 LACTB CXCL8
4 otitis media 31.5 TNF TLR2 LACTB CXCL8
5 pneumonia 31.3 VTN TNF TLR2 LACTB CXCL8
6 cellulitis 31.1 TNF LACTB
7 pericarditis 30.9 VTN TNF CXCL8
8 bacterial conjunctivitis 30.9 TNF CXCL8
9 osteomyelitis 30.9 TNF TLR2 CXCL8
10 pulmonary disease, chronic obstructive 30.9 TNF TLR2 CXCL8
11 neisseria meningitidis infection 30.9 TLR2 OMP LACTB
12 bronchopneumonia 30.8 TNF CXCL8
13 bronchitis 30.8 TNF TLR2 LTF LACTB CXCL8
14 bronchiectasis 30.8 TNF TLR2 CXCL8
15 lung abscess 30.7 TNF LACTB
16 bacterial infectious disease 30.6 TNF TLR2 LTF CXCL8
17 toxic shock syndrome 30.6 TNF TLR2 CXCL8
18 peritonitis 30.6 TNF TLR2 CXCL8
19 endophthalmitis 30.6 TNF TLR2 CXCL8
20 endocarditis 30.5 TNF TLR2 LACTB CXCL8
21 salpingitis 30.5 TNF TLR2
22 urethritis 30.5 TNF TLR2 CXCL8
23 pharyngitis 30.5 TNF LACTB CXCL8
24 tonsillitis 30.4 TNF TLR2 LACTB CXCL8
25 disease by infectious agent 30.4 TNF TLR2 LACTB
26 endometritis 30.4 TNF LACTB CXCL8
27 meningococcal meningitis 30.4 TLR2 CFH
28 bacterial pneumonia 30.3 TNF TLR2 LACTB CXCL8
29 tracheitis 30.3 TNF CXCL8
30 vaginal discharge 30.3 TNF CXCL8
31 vaginitis 30.2 TNF TLR2 CXCL8
32 gastroenteritis 30.2 TNF LACTB CXCL8
33 aseptic meningitis 30.2 TNF LTF CXCL8
34 keratitis, hereditary 30.2 TNF TLR2 CXCL8
35 cystic fibrosis 30.2 TNF TLR2 LTF LACTB CXCL8
36 chlamydia 30.2 TNF TLR2 CXCL8
37 streptococcus pneumonia 30.1 TNF TLR2 CXCL8
38 middle ear disease 30.1 TNF TLR2 CXCL8
39 bacterial sepsis 30.1 TNF TLR2 CXCL8
40 cervicitis 30.1 TNF CXCL8
41 aspiration pneumonitis 30.1 TNF CXCL8
42 bronchiolitis 30.0 TNF TLR2 CXCL8
43 adult respiratory distress syndrome 29.9 TNF TF CXCL8
44 preterm premature rupture of the membranes 29.9 TNF TLR2 CXCL8
45 chronic mucocutaneous candidiasis 29.7 TNF TLR2 CLEC7A
46 periodontitis 29.7 TNF TLR2 CXCL8
47 chlamydia pneumonia 29.7 TNF TLR2 CXCL8
48 aphthous stomatitis 29.7 TNF TLR2 CXCL8
49 asthma 29.7 VTN TNF TLR2 TF CXCL8
50 food allergy 29.7 TNF TLR2 CXCL8

Graphical network of the top 20 diseases related to Haemophilus Influenzae:



Diseases related to Haemophilus Influenzae
Sources

Symptoms & Phenotypes for Haemophilus Influenzae

About this section

MGI Mouse Phenotypes related to Haemophilus Influenzae:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 homeostasis/metabolism MP:0005376 9.28 CFH CLEC7A LACTB LTF OMP TF
Sources

Drugs & Therapeutics for Haemophilus Influenzae

About this section

Drugs for Haemophilus Influenzae (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show all 45)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1 Immunoglobulins Phase 4
2 Antibodies Phase 4
3 Vaccines Phase 4
4
Edetic Acid Approved, Vet_approved Phase 3 60-00-4, 62-33-9 6049
5
Pentetic acid Approved Phase 3 67-43-6
6
Iron Approved Phase 3 7439-89-6 23925 29936
7
Lactitol Approved, Investigational Phase 3 585-86-4 157355
8 PENTA Phase 3
9 Fibrinolytic Agents Phase 3
10 Anticoagulants Phase 3
11 Immunoglobulins, Intravenous Phase 3
12 polysaccharide-K Phase 3
13 Protective Agents Phase 3
14 Iron Chelating Agents Phase 3
15 Calcium, Dietary Phase 3
16 Chelating Agents Phase 3
17 Antidotes Phase 3
18 Adjuvants, Immunologic Phase 3
19 Broncho-Vaxom Phase 3
20 taxane Phase 3
21 Hemagglutinins Phase 3
22 Somatomedin B Phase 3
23 Immunoglobulin E Phase 3
24 Antitoxins Phase 3
25 Heptavalent Pneumococcal Conjugate Vaccine Phase 3
26 Immunologic Factors Phase 3
27
Calcium Nutraceutical Phase 3 7440-70-2 271
28
Neomycin Approved, Vet_approved Phase 1, Phase 2 1404-04-2 8378
29
Streptomycin Approved, Vet_approved Phase 1, Phase 2 57-92-1 19649
30
Aluminum sulfate Approved Phase 1, Phase 2 10043-01-3
31 Pharmaceutical Solutions Phase 2
32 Antibiotics, Antitubercular Phase 1, Phase 2
33 Anti-Bacterial Agents Phase 1, Phase 2
34 Aluminum phosphate Phase 1, Phase 2
35
Benzocaine Approved, Investigational 1994-09-7, 94-09-7 2337
36
tannic acid Approved 1401-55-4
37
BCG vaccine Approved, Investigational
38
Vitamin A Approved, Nutraceutical, Vet_approved 68-26-8, 11103-57-4 445354
39 Anti-Retroviral Agents
40 gamma-Globulins
41 Rho(D) Immune Globulin
42 retinol
43 Retinol palmitate
44 Vitamins
45
Serine Investigational, Nutraceutical 56-45-1 5951

Interventional clinical trials:

(show top 50) (show all 89)
# Name Status NCT ID Phase Drugs
1 A Demonstration Project for the Elimination of Haemophilus Influenzae Type B in Three Rural Alaska Native Villages Completed NCT00153556 Phase 4
2 Phase 4 Study of Haemophilus Influenzae Type b Vaccine in Different Injection Site Completed NCT01761136 Phase 4
3 Immunogenicity and Safety Study of GSK Biologicals' Combined Diphtheria-tetanus-acellular Pertussis-hepatitis B-inactivated Polio-virus and Haemophilus Influenzae Type b Vaccine (Infanrix Hexaâ„¢) (217744) in Healthy Infants Born to Mothers Vaccinated With Boostrixâ„¢ During Pregnancy or Immediately Post-delivery Completed NCT02422264 Phase 4 Prevnar13
4 A Post Marketing Surveillance Study to Monitor the Reactogenicity and Safety of Vaxemâ„¢Hib When Administered According to the Prescribing Information in Korea Completed NCT01404962 Phase 4
5 The Immediate and Longterm Immune Responses of UK Infants and Young Children to a Booster Dose of Hib Vaccine Completed NCT00197782 Phase 4
6 Assess the Safety & Reactogenicity of GSK Biologicals Hib Vaccine Co-administered With Chinese Local DTPw Vaccine When Compared to Chinese Local DTPw Vaccine Administered Alone, in Healthy Infants at 3,4 & 5 Mths of Age Completed NCT00158795 Phase 4
7 Assessment of Long-term Antibody Persistence After a Booster Dose of GSK Biologicals' Hib & Meningococcal C Vaccine (Menitorixâ„¢) 811936 Given at 12-15 Months of Age to Subjects Primed With 3 Doses of Menitorixâ„¢ at 2, 3, 4 Months of Age Completed NCT00454987 Phase 4
8 A Prospective, Open-label, Interventional Phase IV Study to Assess the Safety of EupentaTM Inj. {Fully Liquid Pentavalent Vaccine, Adsorbed Diphtheria-Tetanus-whole-cell Pertussis-Hepatitis B (rDNA [Recombinant-deoxyribonucleic Acid])-Haemophilus Influenzae Type b Conjugate Vaccine} Not yet recruiting NCT04056728 Phase 4
9 A Phase IV, Non-Inferiority, Observer Blind, Randomized Clinical Study Comparing Safety And Immunogenicity Of DTP-HB-Hib Vaccination by Disposable-Syringe Jet Injector To Vaccination By Needle And Syringe In Healthy Infants In India Terminated NCT02409095 Phase 4
10 A Phase III, Double Blind, Parallel-controlled, Randomised Study to Evaluate the Safety and Immunogenicity of Haemophilus Influenzae Type b Conjugate Vaccine in Healthy Children 2 Months to 5 Years of Age Unknown status NCT02560272 Phase 3
11 A Study of Safety and Immunogenicity of 10-valent and 13-valent Pneumococcal Conjugate Vaccines to Inform Policy Regarding Pneumococcal Vaccination of Papua New Guinean Children Unknown status NCT01619462 Phase 3
12 Immune Memory of GSK's DTPw-HBV/Hib Vaccine by Giving Plain PRP Polysaccharide at 10 Mths. Immuno & Reacto of a Booster Dose of DTPw-HBV/Hib or DTPw-HBV or DTPw-HBV+Hib at 15-18 Mths in Infants Previously Primed With DTPw-HBV/Hib Completed NCT00169442 Phase 3
13 A Phase IIIb, Controlled, Open Label, Single-Center, Persistency, Extension Study in Chinese Children After a 2+1 Dose Series of Either CRM197-Conjugate Haemophilus Influenzae Type b Vaccine or Tetanus Toxoid-Conjugate Haemophilus Influenzae Type b Vaccine Completed NCT02139228 Phase 3
14 Assess Reactogenicity & Safety of a Booster of Either Tritanrix-HepB/Hib-MenAC or Tritanrix-HepB/Hiberix Given (Single-blind) at 15-18 (Philippines)/15-24 Mths (Thailand) & a Dose of Mencevax ACWY at 24-30 Mths (Open Label) Completed NCT00228917 Phase 3
15 Assess Immunogenicity, Safety & Reactogenicity of a 4th Dose of GSK Biologicals' Tritanrix-HepB/Hib-MenAC at 15-24 m & of a Dose of Mencevax ACWY at 24-30 m in Subjects Primed With 3 Doses of Tritanrix-HepB/Hib-MenAC Completed NCT00136604 Phase 3
16 A Phase III Open Label, Multi-Center Pediatric Study in China Comparing Booster Doses of Vaxem Hib and Hiberix Vaccines for the Prevention of Haemophilus Influenzae Type b (Hib) Infection Completed NCT01025544 Phase 3
17 A Phase 3 Open-label Study to Evaluate the Immunogenicity and Safety of a Mixed (HEXA/PENTA/HEXA) Primary Series Schedule That Includes V419 (PR5I) at 2 and 6 Months of Age and Pediacel at 4 Months of Age. Completed NCT01839188 Phase 3
18 A Phase III, Observer-blind, Randomized, Controlled, Multicenter Study to Investigate Immunogenicity and Safety of Haemophilus Influenzae Type b Vaccine in 2 - 4 Months Old Healthy Infants in China, According to the Recommended Regimen of 3 Intramuscular Doses Given One Month Apart Completed NCT00808392 Phase 3
19 A Phase III Randomized, Double-Blind, Active-Comparator Controlled Clinical Trial to Study the Safety, Tolerability, and Immunogenicity of V419 in Healthy Infants When Given at 2, 4, and 11 to 12 Months Completed NCT01480258 Phase 3
20 A Randomized, Positive-controlled, Non-inferiority Phase III Clinical Trial of a Haemophilus Influenzae Type b (Hib) Conjugate Vaccine in Healthy Infants and Children Completed NCT02692859 Phase 3
21 Safety and Immunogenicity of Booster Vaccination With PEDIACEL®, a Combined Diphtheria, Tetanus, Five Component Acellular Pertussis, Inactivated Poliomyelitis and Haemophilus Influenzae Type b Conjugate Vaccine (Adsorbed), Compared to Booster Vaccination With Infanrix® Hexa When Both Vaccines Are Co-Administered With Prevenar® to Toddlers 11-18 Months of Age Completed NCT00355654 Phase 3
22 Immunogenicity and Safety of PEDIACEL®, a Combined Diphtheria, Tetanus, Five Component Acellular Pertussis, Inactivated Poliomyelitis and Haemophilus Influenzae Type b Conjugate Vaccine (Adsorbed), Compared to Infanrix®-IPV+Hib When Both Vaccines Are Co-Administered With Prevenar® to Infants and Toddlers at 2, 3, 4 and 12-18 Months of Age Completed NCT00343421 Phase 3
23 A Randomised, Controlled, Double-Blind Study of the Immunogenicity and Safety of PEDIACEL®, a Combined Diphtheria, Tetanus, Five Component Acellular Pertussis, Inactivated Poliomyelitis and Haemophilus Influenzae Type b Conjugate Vaccine (Adsorbed) Compared To Infanrix®-IPV+Hib When Both Vaccines Are Given to Infants Using a Three Dose Immunisation Schedule ("Nordic Schedule" 3-5-12 Months) Completed NCT00287092 Phase 3
24 Immunogenicity and Safety of GSK Biologicals' Combined Diphtheria-tetanus-acellular Pertussis-inactivated Poliovirus and Haemophilus Influenzae Type b (DTPa-IPV/Hib) Conjugate Vaccine Completed NCT02858440 Phase 3
25 A Single-blind, Randomized, Controlled, Multinational Study for the Evaluation of Safety of GlaxoSmithKline (GSK) Biologicals' Investigational Vaccination Regimen Compared to Monovalent Haemophilus Influenzae Type b (Hib) Control Vaccine in Healthy Infants at 2, 4, 6, and 12 to 15 Months of Age. Completed NCT00345579 Phase 3
26 A Phase III, Randomized, Multinational Study, Double-blinded for the Immunogenicity and Consistency Evaluation of 3 Hib-MenCY-TT Vaccine Lots and Single-blinded and Controlled for the Evaluation of Safety and Immunogenicity of GSK Biologicals' Haemophilus Influenzae Type b and Neisseria Meningitidis Serogroups C and Y-tetanus Toxoid Conjugate Vaccine Combined (Hib-MenCY-TT) Compared to Monovalent Hib Vaccine in Healthy Infants at 2, 4, 6, and 12 to 15 Months of Age. Completed NCT00289783 Phase 3
27 A Multicentre, Comparative, Two-arm, Parallel-group, Double-blind, Randomized Phase III Study to Assess Immunogenicity and Safety of LBVH0101 (Haemophilus Influenzae Type b Tetanus Toxoid Conjugate Vaccine) Compared With Hiberixâ„¢ Vaccine in Healthy Infants at Two, Four and Six Months of Age Completed NCT01019772 Phase 3
28 A Study in Healthy Infants of the Safety, Tolerability, and Immunogenicity of Haemophilus Influenzae, Type b/Hepatitis B Vaccine Manufactured With a Modified Process Completed NCT00441012 Phase 3
29 A Phase III Open-label Randomised Study, to Evaluate the Immunogenicity and Safety of the Concomitant Administration of V419 (PR5I) Given at 2, 3 and 4 Months of Age With Two Types of Meningococcal Serogroup C Conjugate (MCC) Vaccines Given at 3 and 4 Months of Age, and Followed by the Administration at 12 Months of Age of a Combined Haemophilus Influenzae Type b-MCC Vaccine Completed NCT01553279 Phase 3
30 A Phase III Study to Assess Immunogenicity and Safety of 4th LBVH0101 Vaccination Compared With 4th Hiberixâ„¢ Vaccination in Healthy Toddlers Who Completed Primary Vaccination in LG-VHCL002 Study Completed NCT01251133 Phase 3
31 Immunogenicity & Safety Study in Preterm & Full-term Infants of GSK Biologicals' Hib-MenC Vaccine, Menitorixâ„¢ Co-administered With Infanrixâ„¢ Penta & Prevenarâ„¢ at 2, 4, 6 Months & as a Booster With Infanrixâ„¢ IPV & Prevenarâ„¢ at 16-18 Months Completed NCT00586612 Phase 3
32 A Phase III Observer Blind Single-Coordinating Center Pediatric Study in China Comparing a Booster Dose of Vaxemâ„¢ Hib to HIBERIX® When Given as Part of a Local Dosing Regimen in Infants Completed NCT01226953 Phase 3
33 Assess Safety & Reactogenicity of DTPa-IPV/Hib Vaccine Admnd at 3 & 4 Mths & DTPa-HBV-IPV/Hib Vaccine Admnd at 5 Mths, Followed by DTPa-IPV/Hib Vaccine at 18 Mths in Infants Who Received hepatitisB Vaccine at Birth & at One Month of Age Completed NCT00325143 Phase 3
34 Demonstrate Non-inferiority of GSK Biologicals' Tritanrixâ„¢-HepB/Hib-MenAC vs Tritanrixâ„¢-HepB/Hiberixâ„¢ With Respect to Anti-HBs Immune Response, When Given to Healthy Infants at 6,10 & 14 Weeks Age, After a Birth Dose of Hepatitis B Vaccine Completed NCT00317122 Phase 3
35 Study to Demonstrate Non-inferiority of GSK Biologicals' Hib-MenC With Priorixâ„¢, Versus MenC-CRM197 Vaccine With Hiberixâ„¢ & Priorixâ„¢ in Toddlers Primed With Hib But Not MenC & to Evaluate Persistence up to 5 Years After Vaccination. Completed NCT00326118 Phase 3
36 Study to Show Non-inferiority of Tritanrixâ„¢-HepB/Hib-MenAC (+/- Hepatitis B Vaccine at Birth) Versus Tritanrixâ„¢-HepB/Hiberixâ„¢ Without Hepatitis B Vacc. at Birth for Antibody Response to All Vaccine Antigens Given in Healthy Infants Completed NCT00290303 Phase 3
37 A Phase III Observer-Blind, Randomized, Controlled, Single-Coordinating Center Pediatric Study in China Comparing Two Doses of a Monovalent Glycoprotein-Conjugated (Diptheria Toxin -CRM197) Vaccine Versus a Tetanus Toxoid-Conjugated Vaccine Using a Local Dosing Regimen in Infants Completed NCT01044316 Phase 3
38 Phase III, Open, Multicenter Study to Assess the Long-Term Persistence of a Booster Dose of GSK Biologicals' Hib-MenC Compared to a Booster Dose of Infanrixâ„¢ Hexa When Given to 14 Month-old Subjects Primed in Study DTPa-HBV-IPV-097 & Boosted in Study Hib-MenC-TT-010 BST: DTPa-HBV-IPV-097 Completed NCT00322335 Phase 3
39 Study to Evaluate the Safety, Reactogenicity & Immunogenicity of a Booster Dose of GSK Biologicals' Hib-MenC Given With Priorixâ„¢, vs Hib-MenC or Priorixâ„¢ Only, in Toddlers (13-14 m) Primed With 3 Doses of Hib (as Part of a DTPa -Containing Vaccine) & MenC-CRM197 Conjugate Vaccines. Completed NCT00263653 Phase 3
40 Demonstrate Non-inferiority of Men-C Immune Response of Hib-MenC With Infanrixâ„¢-IPV Versus a Licensed Men-C Vaccine With Pediacelâ„¢ When Given at 2, 3, 4 Months and the Immunogenicity of Hib-MenC When Given as a Booster Dose at 12-15 Months Completed NCT00258700 Phase 3
41 A Phase III Observer-blind, Randomized, Controlled, Single-coordinating Center Study to Investigate Immunogenicity and Safety of a Monovalent Glycoprotein-conjugated (Diptheria Toxin -CRM197) Hib Vaccine in 13-59 Months Old Healthy Children in China, According to the Recommended Regimen of 1 Dose Completed NCT01125527 Phase 3
42 Single-blind, Randomized, Controlled, Multinational Study for the Evaluation of Safety of GSK Biologicals' Hib-MenCY-TT Vaccine Compared to Monovalent Hib Control Vaccine in Healthy Infants at 2, 4, 6, and 12 to 15 Months of Age. Completed NCT00345683 Phase 3
43 Phase III, Partially Double-blind Study to Evaluate Consistency and Immunogenicity of 3 Lots of GSK Biologicals' Hib Conjugate Vaccine 208108 Versus ActHIB and Pentacel at 2, 4, 6 and 15-18 Months of Age in Healthy Infants Completed NCT01000974 Phase 3
44 Safety and Reactogenicity of GSK Biologicals' DTPa-IPV/Hib (Infanrixâ„¢-IPV/Hib) in Infants Completed NCT00964028 Phase 3
45 The Effect of Polyvalent Mechanical Bacterial Lysate on the Reduction of Nasal Staphylococcus Aureus Carriage in Children With Pollen Allergic Rhinitis Completed NCT04637425 Phase 3 Ismigen;Placebo
46 An Open, Randomised, Comparative, Multicentre Study of the Immunogenicity and Safety of Concomitant Versus Separate Administration of a Combined Measles, Mumps, Rubella and Varicella Live Vaccine (ProQuad®) and a Booster Dose of Infanrix® Hexa in Healthy Children 12 to 23 Months of Age Completed NCT00432042 Phase 3
47 A Phase 3, Open-Label, Randomized, Multi-Center Study to Evaluate the Safety and Immunogenicity After One or Two Doses of Novartis Meningococcal ACWY Conjugate Vaccine Administered to Healthy Infants and Toddlers Completed NCT00667602 Phase 3
48 Multicentre, Randomised, Double Blind, Placebo-controlled Study of the Efficacy and Safety of Broncho-Vaxom (OM 85 BV) in Children Suffering From Atopic Dermatitis Completed NCT03047954 Phase 3 Broncho-Vaxom;Placebo - Cap
49 Immunogenicity and Safety of an Investigational Quadrivalent Meningococcal Conjugate Vaccine Administered Concomitantly With Other Pediatric Vaccines in Healthy Toddlers Completed NCT03205371 Phase 3
50 A Phase 3, Randomized, Double-Blind Study of the Safety, Tolerability, Lot-to-Lot Consistency, Immunogenicity & Non-Interference With Concomitant Vaccinations of Serum Institute of PNEUMOSIL in Healthy Infants in The Gambia Completed NCT03197376 Phase 3

Search NIH Clinical Center for Haemophilus Influenzae

Sources

Genetic Tests for Haemophilus Influenzae

About this section
Sources

Anatomical Context for Haemophilus Influenzae

About this section

MalaCards organs/tissues related to Haemophilus Influenzae:

40
Neutrophil, Bone Marrow, Eye, Skin, Endothelial, B Cells, Lung
Sources

Publications for Haemophilus Influenzae

About this section

Articles related to Haemophilus Influenzae:

(show top 50) (show all 18718)
# Title Authors PMID Year
1
Management of sickle cell disease: current practices and challenges in a northeastern region of the Democratic Republic of the Congo. 61
33594960 2021
2
Acute otitis media and pneumococcal vaccination - an observational cross-sectional study of otitis media among vaccinated and unvaccinated children in Greenland. 61
33407056 2021
3
Outcomes of protracted bacterial bronchitis in children: A 5-year prospective cohort study. 61
33045125 2021
4
Epidemiology, Etiology and Clinical Aspects of Childhood Acute Encephalitis in a Tertiary Pediatric Hospital in Costa Rica. 61
33060517 2021
5
Protective immune responses against Haemophilus influenza type b elicited by a fully-liquid DTaP-IPV-Hib-HepB vaccine (VAXELISâ„¢). 61
33541794 2021
6
Phase variation with altering phosphorylcholine expression of nontypeable Haemophilus influenzae affects bacteria clearance and mucosal immune response in the middle ear and nasopharynx. 61
32684402 2021
7
Determinants of vaccine uptake in HIV-affected families from West Bengal. 61
33545012 2021
8
Increased Respiratory Viral Detection and Symptom Burden Among Patients with Primary Antibody Deficiency: Results from the BIPAD Study. 61
32841749 2021
9
Polarized cytokine release from airway epithelium differentially influences macrophage phenotype. 61
33588245 2021
10
Invasive Haemophilus influenzae type a infection and polyarthritis in a 72-year-old Japanese man: A case report. 61
33602639 2021
11
Presence of Antibodies Against Haemophilus influenzae Serotype a in Alaska Before and After the Emergence of Invasive Infections. 61
32594132 2021
12
Early detection of drug-resistant Streptococcus pneumoniae and Haemophilus influenzae by quantitative flow cytometry. 61
33536509 2021
13
Quantification of residual cetyltrimethylammonium bromide (CTAB) and sodium deoxycholate (DOC) in Haemophilus influenzae type b (Hib) polysaccharide using NMR. 61
33582025 2021
14
Epidemiologic study of Haemophilus influenzae causing invasive and non-invasive disease in Paraguay (1999-2017). 61
32197798 2021
15
Haemophilus influenzae type b and pneumococcal conjugate vaccination coverage in children aged 2-59 months in Malawi. 61
32574099 2021
16
The importance of (at least) a clinical typification of non-typeable Haemophilus influenzae infection. 61
33279275 2021
17
Evaluation of the adequacy of the antimicrobial therapy of invasive Haemophilus influenzae infections: A pharmacokinetic/pharmacodynamic perspective. 61
32636039 2021
18
Trough Concentrations of Specific Antibodies in Primary Immunodeficiency Patients Receiving Intravenous Immunoglobulin Replacement Therapy. 61
33557365 2021
19
Triggering Closure of a Sialic Acid TRAP Transporter Substrate Binding Protein through Binding of Natural or Artificial Substrates. 61
33316271 2021
20
Increased serum bactericidal activity of autologous serum in C2 deficiency after vaccination against Haemophilus influenzae type b, and further support for an MBL-dependent C2 bypass mechanism. 61
33509693 2021
21
Impact of Haemophilus influenzae type b combination vaccination on asthma symptoms and pneumonia in 5-year-old children in rural Bangladesh: a longitudinal study and comparison with a previous cross-sectional study. 61
33536028 2021
22
The role of typical and atypical pathogens in acute exacerbations of chronic obstructive pulmonary disease. 61
33030784 2021
23
Macrophage Depletion in CCR2-/- Mice Delays Bacterial Clearance and Enhances Neutrophil Infiltration in an Acute Otitis Media Model. 61
32572481 2021
24
Role of Surfactant Protein D in Experimental Otitis Media. 61
33556949 2021
25
The effect of pneumococcal conjugate vaccines on otitis media from 2005 to 2013 in children aged ≤5 years: a retrospective cohort study in two Swedish regions. 61
32574101 2021
26
Analysis of Inflammatory Signaling in Human Middle Ear Cell Culture Models of Pediatric Otitis Media. 61
32433794 2021
27
Ophthalmia neonatorum in a tertiary referral children's hospital: A retrospective study. 61
33583215 2021
28
Miller Fisher Syndrome Triggered by Infections: A Review of the Literature and a Case Report. 61
33570020 2021
29
AT-RvD1 Mitigates Secondhand Smoke-Exacerbated Pulmonary Inflammation and Restores Secondhand Smoke-Suppressed Antibacterial Immunity. 61
33558371 2021
30
The increasing importance of Haemophilus influenzae in community-acquired pneumonia: results from a Danish cohort study. 61
33231116 2021
31
Treatment of Community-Acquired Pneumonia: A Focus on Lefamulin. 61
33528794 2021
32
Microbial aetiology of acute rhinosinusitis during pregnancy. 61
32830808 2021
33
Effects of message order and active participation on vaccine risk communication. 61
33599373 2021
34
Structural Basis for Toxin Inhibition in the VapXD Toxin-Antitoxin System. 61
33096014 2021
35
Broad range detection of viral and bacterial pathogens in bronchoalveolar lavage fluid of children to identify the cause of lower respiratory tract infections. 61
33546631 2021
36
Systematic Review and Meta-analysis of the Change in Pharyngeal Bacterial Cultures After Pediatric Tonsillectomy. 61
32689869 2021
37
Bacterial Growth Mindset: Structural Plasticity in Defense Systems. 61
33545061 2021
38
Exploring the evidence behind the comparable impact of the pneumococcal conjugate vaccines PHiD-CV and PCV13 on overall pneumococcal disease. 61
33605846 2021
39
Evolution of Microbial Genomics: Conceptual Shifts over a Quarter Century. 61
33541841 2021
40
Nationwide surveillance of bacterial pathogens isolated from children conducted by the surveillance committee of Japanese Society of Chemotherapy, the Japanese Association for Infectious Diseases, and the Japanese Society for Clinical Microbiology in 2017: General overview of pathogenic antimicrobial susceptibility. 61
33277177 2021
41
Upper Respiratory Microbiota in Relation to Ear and Nose Health Among Australian Aboriginal and Torres Strait Islander Children. 61
33393596 2021
42
Proceedings of a workshop to discuss the epidemiology of invasive Haemophilus influenzae disease with emphasis on serotype a and b in the Americas, 2019. 61
33358264 2021
43
Genomic insights of international clones of Haemophilus influenzae causing invasive infections in vaccinated and unvaccinated infants. 61
33259886 2021
44
Cefotaxime resistance in invasive Haemophilus influenzae isolates in Germany 2016-19: prevalence, epidemiology and relevance of PBP3 substitutions. 61
33501993 2021
45
Genome-wide analysis of DNA uptake across the outer membrane of naturally competent Haemophilus influenzae. 61
33490915 2021
46
Profiling of Haemophilus influenzae strain R2866 with carbohydrate-based covalent probes. 61
33355321 2021
47
Highly selective impedimetric determination of Haemophilus influenzae protein D using maze-like boron-doped carbon nanowall electrodes. 61
33076151 2021
48
For which infants with viral bronchiolitis could it be deemed appropriate to use albuterol, at least on a therapeutic trial basis? 61
33528944 2021
49
Add-on azithromycin reduces sputum cytokines in non-eosinophilic asthma: an AMAZES substudy. 61
33414242 2021
50
Utility of immunology, microbiology, and helminth investigations in clinical assessment of severe asthma. 61
33356678 2021
Sources

Variations for Haemophilus Influenzae

About this section
Sources

Expression for Haemophilus Influenzae

About this section
Search GEO for disease gene expression data for Haemophilus Influenzae.
Sources

Pathways for Haemophilus Influenzae

About this section

Pathways related to Haemophilus Influenzae according to GeneCards Suite gene sharing:

(show all 13)
# Super pathways Score Top Affiliating Genes
1
IL-17 Family Signaling Pathways 64
Show member pathways
 12.03 TNF TLR2 CXCL8
2
Proteoglycans in cancer 36
12 VTN TNF TLR2
3
Diseases associated with the TLR signaling cascade 65
Show member pathways
 11.95 TNF TLR2 CXCL8
4
Tuberculosis 36
11.89 TNF TLR2 CLEC7A
5
Bacterial infections in CF airways 23
Show member pathways
 11.83 TNF TLR2 CXCL8
6
Sudden Infant Death Syndrome (SIDS) Susceptibility Pathways 1
11.79 TNF TF CXCL8
7
Amoebiasis 36
11.51 TNF TLR2 CXCL8
8
Rheumatoid arthritis 36
11.4 TNF TLR2 CXCL8
9
Phagocytosis of Microbes 63
11.26 VTN TLR2 CLEC7A
10
Legionellosis 36
10.89 TNF TLR2 CXCL8
11
EBV LMP1 signaling 1
10.86 TNF CXCL8
12
Overview of nanoparticle effects 1
10.65 TNF CXCL8
13
Malaria 36
10.5 TNF TLR2 CXCL8
Sources

GO Terms for Haemophilus Influenzae

About this section

Cellular components related to Haemophilus Influenzae according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular space GO:0005615 9.73 VTN TNF TF LTF CXCL8 CFH
2 blood microparticle GO:0072562 9.33 VTN TF CFH
3 recycling endosome GO:0055037 9.13 TNF TF LTF
4 cell surface GO:0009986 9.02 TNF TLR2 TF LTF CLEC7A

Biological processes related to Haemophilus Influenzae according to GeneCards Suite gene sharing:

(show all 15)
# Name GO ID Score Top Affiliating Genes
1 positive regulation of gene expression GO:0010628 9.71 TNF TLR2 CXCL8 CLEC7A
2 immune response GO:0006955 9.67 VTN TNF TLR2 CXCL8
3 positive regulation of NF-kappaB transcription factor activity GO:0051092 9.61 TNF TLR2 LTF
4 inflammatory response GO:0006954 9.56 TNF TLR2 CXCL8 CLEC7A
5 lipopolysaccharide-mediated signaling pathway GO:0031663 9.55 TNF TLR2
6 osteoclast differentiation GO:0030316 9.54 TNF TF
7 microglial cell activation GO:0001774 9.52 TNF TLR2
8 positive regulation of wound healing GO:0090303 9.51 VTN CLEC7A
9 positive regulation of cytokine production involved in inflammatory response GO:1900017 9.49 TNF CLEC7A
10 positive regulation of receptor-mediated endocytosis GO:0048260 9.48 VTN TF
11 iron ion transport GO:0006826 9.46 TF LTF
12 embryonic digestive tract development GO:0048566 9.32 TNF CXCL8
13 response to molecule of bacterial origin GO:0002237 9.16 TLR2 CXCL8
14 positive regulation of interleukin-6 production GO:0032755 9.13 TNF TLR2 CLEC7A
15 positive regulation of interleukin-8 production GO:0032757 8.8 TNF TLR2 CLEC7A

Molecular functions related to Haemophilus Influenzae according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 lipopolysaccharide binding GO:0001530 9.16 TLR2 LTF
2 heparin binding GO:0008201 9.13 VTN LTF CFH
3 pattern recognition receptor activity GO:0038187 8.62 TLR2 CLEC7A
Sources

Sources for Haemophilus Influenzae

About this section
3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
20 GARD
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
53 NINDS
54 Novoseek
56 OMIM via Orphanet
57 OMIM® (Updated 05-Mar-2021)
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
The MalaCards human disease database index: 1-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Content
Loading form....